A Study of LY3819469 in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) \[Lp(a)\] levels. How the body processes the study drug and the effect of the study drug on blood Lp(a) levels will also be investigated. Part B will mainly evaluate the safety and tolerability of LY3819469 as well as how the body processes the study drug in Japanese participants. The study may last up to 53 and 29 weeks for each participant in Parts A and B, respectively.
Key facts
- Study ID
- NCT04914546
- Run by
- Eli Lilly and Company
- People needed
- 66
- Starts
- 2021-06-14
- Expected to finish
- 2022-11-09
- Last updated by the study team
- 2022-11-21
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Female participants must not be able to get pregnant and male participants must agree to adhere to contraception restrictions
- Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
- For Part B, participants should be of first-generation Japanese origin
You may not qualify if…
- Are currently participating in or completed a clinical trial within the last 30 days
- Are heavy alcohol drinkers or heavy cigarette smokers
- Have donated blood of more than 500 milliliters (mL) in the last 3 months
Where it is running
- Altasciences Clinical Los Angeles, Inc — Cypress, California, United States
- Clinical Pharmacology of Miami — Miami, Florida, United States
- Qps-Mra, Llc — Miami, Florida, United States
- Endeavor Clinical Trials — San Antonio, Texas, United States
- Lilly Centre for Clinical Pharmacology — Singapore, Singapore
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.